| Delta hit Israel in June, just as the country began to reap the benefits of one of the world’s fastest vaccine roll-outs |
Less than a month into a COVID-19 vaccine booster drive, Israel is seeing signs of an impact on the country’s high infection and severe illness rates fuelled by the fast-spreading delta variant, officials and scientists say.
Delta hit Israel in June, just as the country began to reap the benefits of one of the world’s fastest vaccine roll-outs.
With an open economy and most curbs scrapped, Israel went from single-digit daily infections and zero deaths to around 7,500 daily cases last week, 600 people hospitalised in serious condition and more than 150 people dying in that week alone.
On 30th July, it began administering a third dose of the Pfizer/BioNtech vaccine to people over 60, the first country to do so.
The rate of disease spread among vaccinated people aged 60 and above – known as the reproduction rate – began falling steadily around 13th August, and has dipped below one, indicating that each infected person is transmitting the virus to fewer than one other person. A reproduction rate of less than one means an outbreak is subsiding.
Scientists said booster shots are having an impact on infections, but other factors are likely contributing to the decline as well.
“The numbers are still very high but what has changed is that the very high increase in the rate of infections and severe cases has diminished, as has the pace at which the pandemic is spreading,” said Eran Segal, Data Scientist, Weizmann Institute of Science and an adviser to the government.
“This is likely due to the third booster shots, an uptake in people taking the first dose and the high number of people infected per week, possibly up to 100,000, who now have natural immunity,” Segal said.
After reaching one of the highest per-capita infection rates in the world this month, the question now is whether Israel can battle its way out of a fourth outbreak without imposing another lockdown that would damage its economy.
Evidence has emerged showing that while the vaccine is still highly effective in preventing serious illness, its protection diminishes with time. However, there is no consensus among scientists and agencies that a third dose is necessary, and the World Health Organization (WHO) has said more of the world should be vaccinated with a first dose before people receive a third dose.
The United States has announced plans to offer booster doses to all Americans, eight months after their second vaccine dose, citing data showing diminishing protection. Canada, France and Germany have also planned booster campaigns.
About a million of Israel’s 9.3 million population have so far chosen not to vaccinate at all and children under 12 are still not eligible for the shots.
According to Doron Gazit, a member of the Hebrew University’s COVID-19 expert team which advises government, the rise in cases of severely ill vaccinated people in the 60 and older group has been steadily slowing to a halt in the last 10 days.
“We attribute this to the booster shots and to more cautious behaviour recently,” Gazit said.
More than half of those over 60 have received a third jab, according to the Health Ministry.
The rate of new severe cases among unvaccinated patients aged 70 and older is now seven times that of vaccinated patients, and the gap will continue to grow as long as infections rise, according to Gazit. Among those over 50, that gap is four-fold.
“We are optimistic, but very cautious,” Nitzan Horowitz, Health Minister, Israel said. “It gives us more time, slows the spread and we’re moving away from lockdown.”
But even if the boosters are slowing the pandemic’s pace, it is unlikely to fend delta off entirely.
Dvir Aran, Biomedical Data Scientist, Technion – Israel’s Institute of Technology, said that while cases are retreating, other measures are needed alongside boosters to stop the pandemic. “It will take a long time until enough people get a third dose and until then thousands more people will be getting seriously ill.”
Since delta’s surge, Israel has reimposed indoor mask wearing, limitations on gatherings and ramped up rapid testing.
Its “living with COVID” policy will be tested come September, when schools reopen after summer break and when the Jewish holiday season starts, with families traditionally gathering to celebrate.
In the second half of 2022, China unveiled the details of its data export regulations, providing further explanations to its existing laws and regulations on data.
The current energy crisis has reached an unsustainable level for the European chemical industry. For the first time ever, the EU imports more chemicals than it exports, both in volume and value, resulting in a trade deficit of € 5.6 bn for the first half of 2022.
Endocrine Disrupting Chemicals (also referred to as hormone disruptors or EDCs) are synthetic chemicals that are not produced by the human body and that disrupt the normal functioning of humans and animals.
The shipping industry is now returning to normality and is in a downward spiral. The cost of shipping goods from China has slumped to the lowest level in more than two years as the world economy stumbles, dimming prospects for container carriers that turned in record profits during the pandemic.
No precipitous plunge in container shipping rates, just ‘orderly’ decline.
The global food and beverage market size is expected to grow from $5.8 trillion in 2021 to $6.4 trillion in 2022 at a growth rate of 9.7%. The food and beverage market size is expected to grow to $8.9 trillion in 2026 at a compound annual growth rate of 8.7%.
The amendment makes QR codes mandatory on every active pharmaceutical ingredient. The Amendment Rules will come into force from January 01, 2023.
On June 22, 2022, the Commission adopted pioneering proposals to restore damaged ecosystems and bring nature back across Europe, from agricultural land and seas, to forests and urban environments. The Commission also proposes to reduce the use and risk of chemical pesticides by 50% by 2030.
According to New York Times, in a small clinical trial, 18 patients took a drug called Dostarlimab for around six months, and in the end, every one of them saw their tumours disappear.